Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InspireMD ( (NSPR) ) has issued an update.
InspireMD, Inc. has announced the submission of a Premarket Approval (PMA) application to the FDA for its CGuard Prime Carotid Stent System, following positive results from its C-GUARDIANS clinical trial. The trial showed a lower major adverse event rate than any previous trial of its kind, signifying a potential breakthrough in stroke prevention and carotid artery disease treatment. The company anticipates a U.S. commercial launch in the first half of 2025, pending approval.
Learn more about NSPR stock on TipRanks’ Stock Analysis page.
